• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Robert L. Martuza, MD


  • Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.Neuro Oncology. 2014 Aug(8):1057-66.
  • Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE.Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.Science. 2014 Jun 20(6190):1396-401.
  • Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE.Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.Cell. 2014 Apr 24;157(3):580-94.
  • Sheth SA, Tirino JL, Martuza RL.Vestibular schwannoma: suboccipital approach.Neurosurg Focus. 2014 Jan;36(1 Suppl):1.
  • Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD.Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12006-11.
  • Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.Neoplasia. 2013 Jun;15(6):591-9.
  • Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE.An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.Cell Rep. 2013 May 30;3(5):1567-79.
  • Las Heras F, Martuza R, Caruso P, Rincon S, Stemmer-Rachamimov A.24-year-old woman with an internal auditory canal mass.Brain Pathol. 2013 May;23(3):361-2.
  • Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K.Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.Mol Ther. 2013 Jan;21(1):68-77.
  • Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL.Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.Stem Cells Transl Med. 2012 Apr;1(4):322-32.
  • Ginat DT, Martuza RL.Postoperative imaging of vestibular schwannomas.Neurosurg Focus. 2012 Sep;33(3):E18.
  • Peterfreund RA, Luman E, Martuza RL.Anesthesia for suboccipital craniotomy in a patient with lymphangioleiomyomatosis: a case report.Case Rep Pulmonol. 2012;2012:804789.
  • Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT.Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.Neurosurgery. 2012 Sep;71(3):741-8; discussion 748.
  • Elstner A, Stockhammer F, Nguyen-Dobinsky TN, Nguyen QL, Pilgermann I, Gill A, Guhr A, Zhang T, von Eckardstein K, Picht T, Veelken J, Martuza RL, von Deimling A, Kurtz A.Identification of diagnostic serum protein profiles of glioblastoma patients.J. Neurooncol. 2010 Jul 9.
  • Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RL.Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.Gene Ther. 2010 Jun;17(6):805-10.
  • Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL.Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.Cancer Res. 2010 May 15;70(10):3890-5.
  • Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza .An oncolytic herpes simplex virus armed with a xenogeneic homologue of prostatic acid phosphatase enhances anti-tumor efficacy in prostate cancer .Gene Ther..
  • Stankovic KM, Mrugala MM, Martuza RL, Silver M, Betensky RA, Nadol JB, Stemmer-Rachamimov AO.Genetic determinants of hearing loss associated with vestibular schwannomas.Otol. Neurotol. 2009 Aug;30(5):661-7.
  • Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL.Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.Cancer Gene Ther. 2009 Jul;16(7):551-60.
  • Wakimoto H,Kesari S,Farrell CJ,Curry WT Jr,Zaupa C,Aghi M,Kuroda T,Stemmer-Rachamimov A,Shah K,Liu TC,Jeyaretna DS,Debasitis J,Pruszak J,Martuza RL,Rabkin SD.Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.Cancer Res. 2009 Apr 15;69(8):3472-81.
  • Sasportas LS,Kasmieh R,Wakimoto H,Hingtgen S,van de Water JA,Mohapatra G,Figueiredo JL,Martuza RL,Weissleder R,Shah K.Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7.
  • Aghi MK,Carter BS,Cosgrove GR,Ojemann RG,Amin-Hanjani S,Martuza RL,Curry WT Jr,Barker FG 2nd.Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.Neurosurgery. 2009 Jan;64(1):56-60; discussion 60.
  • Farrell CJ,Zaupa C,Barnard Z,Maley J,Martuza RL,Rabkin SD,Curry WT Jr.Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells.Clin Cancer Res. 2008 Dec 1;14(23):7711-6.
  • Farassati F,Pan W,Yamoutpour F,Henke S,Piedra M,Frahm S,Al-Tawil S,Mangrum WI,Parada LF,Rabkin SD,Martuza RL,Kurtz A.Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.Am J Pathol. 2008 Dec;173(6):1861-72.
  • Aghi MK,Liu TC,Rabkin S,Martuza RL.Hypoxia enhances the replication of oncolytic herpes simplex virus.Mol Ther. 2009 Jan;17(1):51-6.
  • Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL.Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects.Mol Ther. 2008 Jun;16(6):1041-7.
  • Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A.The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.J Neurooncol. 2008 May;88(1):43-50.
  • Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, Kaufman CS, Kaur B, Lawler SE, Lee RJ, Marsh CB, Brat DJ, van Rooijen N, Stemmer-Rachamimov AO, Hochberg FH, Weissleder R, Martuza RL, Chiocca EA.Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.Cancer Res. 2007 Oct 1;67(19):9398-406.
  • Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL.Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.Cancer Res. 2007 Oct 1;67(19):9371-9.
  • Liu TC, Wakimoto H, Martuza RL, Rabkin SD.Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.Clin Cancer Res. 2007 Oct 1;13(19):5897-902.
  • Jeyaretna DS, Rabkin SD, Martuza RL.Oncolytic herpes simplex virus therapy for peripheral nerve tumors.Neurosurg Focus. 2007;22(6):E4. Review.
  • Aghi M, Rabkin S, Martuza RL.Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.Clin Neurosurg. 2006;53:65-76.
  • Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO.Treatment of Implantable NF2 Schwannoma Tumor Models with Oncolytic Herpes Simplex Virus G47Delta.Cancer Gene Ther. 2007 May;14(5):460-7.
  • Aghi M, Rabkin SD, Martuza RL.Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.Cancer Res. 2007 Jan 15;67(2):440-4.
  • Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD.Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.Clin Cancer Res. 2006 Nov 15;12(22):6791-9.
  • Martuza RL.Vestibular schwannoma.J Neurosurg. 2006 Oct;105(4):526; discussion 526.
  • Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A.Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.Mol Ther. 2006 Dec;14(6):789-97.
  • Kuroda T, Rabkin SD, Martuza RL.Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.Cancer Res. 2006 Oct 15;66(20):10127-35.
  • Kuroda T, Martuza RL, Todo T, Rabkin SD.Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.BMC Biotechnol. 2006;6:40.
  • Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL.Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.Clin Cancer Res. 2006 May 1;12(9):2919-27.
  • Messerli SM, Prabhakar S, Tang Y, Mahmood U, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO.Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.Hum Gene Ther. 2006 Jan;17(1):20-30.
  • Aghi M, Rabkin S, Martuza RL.Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.J Natl Cancer Inst. 2006 Jan 4;98(1):38-50.
  • Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T.Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.Cancer Res. 2005 Dec 1;65(23):10663-8.
  • Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL.Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.Cancer Gene Ther. 2006 Mar;13(3):253-65.
  • Weber DC, Chan AW, Bussiere MR, Harsh GR, Ancukiewicz M, Barker FG, Thornton AT, Martuza RL, Nadol JB, Chapman PH, Loeffler JS.Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity.Neurosurgery. 2003 Sep;53(3):577-86; discussion 586-8.
  • Nikolic B, Feigenbaum F, Abbara S, Martuza RL, Schellinger D.CT changes of an intracranial granulocytic sarcoma on short-term follow-up.AJR Am J Roentgenol. 2003 Jan;180(1):78-80.
  • Kurtz A, Martuza RL.Antiangiogenesis in neurofibromatosis 1.J Child Neurol. 2002 Aug;17(8):578-84; discussion 602-4,.
  • Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL.Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer.Neoplasia. 2001 Sep-Oct;3(5):451-6.
  • Kirn D, Martuza RL, Zwiebel J.Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.Nat Med. 2001 Jul;7(7):781-7.
  • Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL.Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates.Hum Gene Ther. 2001 May 20;12(8):999-1010.
  • Toda M, Martuza RL, Rabkin SD.Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.Gene Ther. 2001 Feb;8(4):332-9.
  • Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz A.Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.Exp Neurol. 2001 May;169(1):64-71.
  • Wu A, Mazumder A, Martuza RL, Liu X, Thein M, Meehan KR, Rabkin SD.Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation.Cancer Res. 2001 Apr 1;61(7):3009-15.
  • Todo T, Martuza RL, Dallman MJ, Rabkin SD.In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.Cancer Res. 2001 Jan 1;61(1):153-61.
  • Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RL.Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.Mol Ther. 2000 Dec;2(6):588-95.
  • Toda M, Martuza RL, Rabkin SD.Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.Mol Ther. 2000 Oct;2(4):324-9.
  • Chahlavi A, Todo T, Martuza RL, Rabkin SD.Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.Neoplasia. 1999 Jun;1(2):162-9.
  • Moulding HD, Martuza RL, Rabkin SD.Clinical mutations in the L1 neural cell adhesion molecule affect cell-surface expression.J Neurosci. 2000 Aug 1;20(15):5696-702.
  • Sandhu FA, Martuza RL.Craniofacial hemangiopericytoma associated with oncogenic osteomalacia: case report.J Neurooncol. 2000;46(3):241-7.
  • Todo T, Rabkin SD, Martuza RL.Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.Cancer Gene Ther. 2000 Jun;7(6):939-46.
  • Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL.Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.Gene Ther. 2000 May;7(10):867-74.
  • Martuza RL.Conditionally replicating herpes vectors for cancer therapy.J Clin Invest. 2000 Apr;105(7):841-6.
  • Sundaresan P, Hunter WD, Martuza RL, Rabkin SD.Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.J Virol. 2000 Apr;74(8):3832-41.
  • Mashour GA, Martuza RL, Kurtz A.Induction of melanogenic abnormalities in NF1+/- mutant mice by DMBA.J Invest Dermatol. 1999 Dec;113(6):1133-4.
  • Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL.Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.Hum Gene Ther. 1999 Nov 20;10(17):2741-55.
  • Todo T, Rabkin SD, Chahlavi A, Martuza RL.Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.Hum Gene Ther. 1999 Nov 20;10(17):2869-78.
  • Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL.Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.Hum Gene Ther. 1999 Sep 1;10(13):2237-43.
  • Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD.Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo.Gene Ther. 1999 Apr;6(4):564-72.
  • Mashour GA, Wang HL, Cabal-Manzano R, Wellstein A, Martuza RL, Kurtz A.Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1.J Invest Dermatol. 1999 Sep;113(3):398-402.
  • Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD.Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.J Virol. 1999 Aug;73(8):6319-26.
  • Toda M, Rabkin SD, Kojima H, Martuza RL.Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity.Hum Gene Ther. 1999 Feb 10;10(3):385-93.
  • New KC, Gale K, Martuza RL, Rabkin SD.Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase.Brain Res Mol Brain Res. 1998 Oct 30;61(1-2):121-35.
  • Toda M, Rabkin SD, Martuza RL.Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.Hum Gene Ther. 1998 Oct 10;9(15):2177-85.
  • Toda M, Martuza RL, Kojima H, Rabkin SD.In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.J Immunol. 1998 May 1;160(9):4457-64.
  • Martuza RL.Act locally, think globally.Nat Med. 1997 Dec;3(12):1323.
  • Miyatake S, Martuza RL, Rabkin SD.Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.Cancer Gene Ther. 1997 Jul-Aug;4(4):222-8.
  • Miyatake S, Iyer A, Martuza RL, Rabkin SD.Transcriptional targeting of herpes simplex virus for cell-specific replication.J Virol. 1997 Jul;71(7):5124-32.
  • Yazaki T, Martuza RL, Rabkin SD.Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration.Brain Res Mol Brain Res. 1996 Dec 31;43(1-2):311-20.
  • Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI.Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.Mol Pharmacol. 1996 Aug;50(2):236-42.
  • Viola JJ, Martuza RL.Gene therapies for glioblastomas.Baillieres Clin Neurol. 1996 Jun;5(2):413-24.
  • Takamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL.Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470.J Neurosurg. 1993 Mar;78(3):470-6.